Temiz, Selami AykutÖzer, İlkayAtaseven, ArzuFındık, Sıddıka2020-01-182020-01-182019Temiz, S. A., Özer, I., Ataseven, A., Fındık, S. (2019). A case of entecavir-associated bullous fixed drug eruption and a review of literature. Turkish Journal of Gastroenterology, 30, 3, 299-302.1300-49482148-5607https://app.trdizin.gov.tr/makale/TWprNE1UY3hNUT09/a-case-of-entecavir-associated-bullous-fixed-drug-eruption-and-a-review-of-literaturehttps://hdl.handle.net/20.500.12452/2368WOS:000462167400013PubMed ID:30459136Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the samesite(s), generally observed following every intake of a causative drug. Delayed-type cellular hypersensitivity (Type IVC) is considered toplay a role in FDE etiology. Several antibiotics, barbiturates, oral contraceptives, nonsteroidal anti-inflammatory drugs, laxative-containing phenolphthalein, metronidazole, and quinine are known to be the primary drugs responsible for FDE. Bullous FDE, on the otherhand, is a relatively rare form of FDE. Hepatitis B is a significant worldwide health problem, and entecavir is a common nucleoside(deoxyguanosine) analog used for treating hepatitis B; however, it has various side effects, such as lactic acidosis, myalgia, azotemia,hypophosphatemia, headache, diarrhea, pancreatitis, and neuropathy, and, in rare cases, cutaneous drug eruption. Our aim is to presenta case of entecavir-associated bullous drug reaction, which has not been reported in the literature. Furthermore, we performed a reviewof literature to compile previously reported entecavir-associated drug reactions.eninfo:eu-repo/semantics/openAccessBullous fixed drug eruptionEntecavirHepatitis BFixed drug eruptionArticle30329930230459136Q3WOS:000462167400013Q410.5152/tjg.2018.17887